Skip to main content
SpringerLink
Log in

Current progress in the prediction of chemosensitivity for breast cancer

  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Advances in chemotherapy have improved the prognosis of patients with breast cancer significantly. Individualization is important for optimization of chemotherapy. The prediction of tumor sensitivity to anticancer agents has been intensively investigated for that purpose. There have been 2 approaches to predict the efficacy of drugs against individual tumors, drug-sensitivity tests and molecular marker genes. Although some of these tests are already available clinically, the prediction of chemosensitivity remains a goal to be achieved.

Several studies with microarrays revealed that comprehensive analyses of genes may provide useful information for determining the chemosensitivity of cancer. We have started to use a cDNA microarray to study the chemosensitivity of breast cancer. Taken together with recent data, studies for drug sensitivity should provide insights into the mechanisms of drug sensitivity and the optimal design of more effective treatment strategies in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

pCR:

Pathological complete response

HDRA:

Histoculture drug response assay

TopoII:

Topoisomerase II alpha

References

  1. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193):J Clin Oncol 21:588–592, 2003.

    Article  PubMed  Google Scholar 

  2. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.J Clin Oncol 17:2355–2364, 1999.

    PubMed  CAS  Google Scholar 

  3. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/ metastatic breast cancer.Ann Oncol 12:1247–1254, 2001.

    Article  PubMed  CAS  Google Scholar 

  4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16:2672–2685, 1998.

    PubMed  CAS  Google Scholar 

  5. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Result from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of the National Cancer Institute Monographs 30:96–102, 2001.

    PubMed  Google Scholar 

  6. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, Nagura H, Ogawa N, Hoffman RM, and the Chemosensitivity Study group for the Histoculture Drug-Response Assay: Potential of the Histoculture Drug-Response Assay to contribute to cancer patient survival.Clin Can Res 1:1537–1543, 1995.

    CAS  Google Scholar 

  7. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: earbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.J Natl Cancer Inst 90:1361–1370, 1998.

    Article  PubMed  CAS  Google Scholar 

  8. Park K, Kim J, Lim S, Han S: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.Eur J Cancer 39:631–634, 2003.

    Article  PubMed  CAS  Google Scholar 

  9. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.Clin Cancer Res 3:593–600, 1997.

    PubMed  CAS  Google Scholar 

  10. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, Skoog L: Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relapse-free survival.Acta Oncol 38:597–601, 1999.

    Article  PubMed  CAS  Google Scholar 

  11. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer.Nature 415:530–536, 2002.

    Article  Google Scholar 

  12. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 98:10869–10874, 2001.

    Article  PubMed  CAS  Google Scholar 

  13. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN: A gene expression database for the molecular pharmacology of cancer.Nature Genetics 24:236–244, 2000.

    Article  PubMed  CAS  Google Scholar 

  14. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines.Cancer Res 62:1139–1147, 2002.

    PubMed  CAS  Google Scholar 

  15. Ichikawa Y, Ishikawa T, Takahashi S, Hamaguchi Y, Morita T, Nishizuka I, Yamaguchi S, Endo I, Ike H, Togo S, Oki S, Shimada H, Kadota K, Nakamura S, Goto H, Nitanda H, Satomi S, Sakai T, Narita I, Gejyo F, Tomaru Y, Shimizu K, Hayashizaki Y, Okazaki Y: Identification of genes regulating colorectal carcino-genesis by using the algorithm for diagnosing malignant state method.Biochem Biophys Res Commun 296:497–506, 2002.

    Article  PubMed  CAS  Google Scholar 

  16. Nishizuka I, Ishikawa T, Hamaguchi Y, Kamiyama M, Ichikawa Y, Kadota K, Miki R, Tomaru Y, Mizuno Y, Tominaga N, Yano R, Goto H, Nitanda H, Togo S, Okazaki Y, Hayashizaki Y, Shimada H: Analysis of gene expression involved in brain metastasis from breast cancer using cDNA microarray.Breast Cancer 9:26–32, 2002.

    Article  PubMed  Google Scholar 

  17. Morita T, Togo S, Kubota T, Kamimukai N, Nishizuka I, Kobayashi T, Ichikawa Y, Ishikawa T, Takahashi S, Matsuo K, Tomaru Y, Okazaki Y, Hayashizaki Y, Shimada H: Mechanism of postoperative liver failure after excessive hepatectomy investigated using a cDNA microarray.J Hepatobiliary Pancreat Surg 9:352–359, 2002

    Article  PubMed  Google Scholar 

  18. Kadota K, Miki R, Bono H, Shimizu K, Okazaki Y, Hayashizaki Y: Preprocessing implementation for microarray (PRIM): an efficient method for processing cDNA microarray data.Physiol Genomics 4:183–188, 2001.

    PubMed  CAS  Google Scholar 

  19. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV: Monitoring the expression Profiles of Doxorubicin-induced and Doxorubicin-resistant Cancer Cells by cDNA Microarray.Cancer Res 60:4161–4166, 2000.

    PubMed  CAS  Google Scholar 

  20. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ, International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.J Clin Oncol 21:2600–2608, 2003.

    Article  PubMed  Google Scholar 

  21. Pusztai L, Ayers M, Simmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN, Stec J: Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/ FAC chemotherapy in breast cancer.ASCO abstract 1, 2003.

Download references

Author information

Authors and Affiliations

  1. Graduate School of Surgical Oncology, Yokohama City University School of Medicine, Japan

    Daisuke Shimizu, Yasushi Ichikawa, Shinji Togo & Hiroshi Shimada

  2. Department of General Surgery, Yokohama City University Medical Center, 4-57 Urafunecho, Minami-ku, 232-0024, Yokohama, Japan

    Takashi Ishikawa

  3. Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), Japan

    Daisuke Shimizu & Yoshihide Hayasizaki

  4. Division of Functional Genomics & Systems Medicine, Research Center for Genomic Medicine, Saitama Medical School, Japan

    Yasushi Okazaki

Authors
  1. Daisuke Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasushi Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinji Togo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshihide Hayasizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasushi Okazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Ishikawa.

About this article

Cite this article

Shimizu, D., Ishikawa, T., Ichikawa, Y. et al. Current progress in the prediction of chemosensitivity for breast cancer. Breast Cancer 11, 42–48 (2004). https://doi.org/10.1007/BF02968001

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968001

Key words

Search

Navigation